Truly human antibody therapeutics.
Humans mount lasting antibody responses to infectious diseases and cancer. Abterra Bio uses next-generation sequencing, mass spectrometry, and machine learning to comprehensively map the antibody response, and rapidly identify better therapeutic antibodies. We’ve built an interdisciplinary team of data scientists and biologists to re-imagine how antibody therapeutics are developed.
Our Services
Abterra Bio technology is built on decades of experience in antibody sequencing and analysis. Click on the services below to see how we can help you!
REPTOR™
Next-Gen Sequencing Hybridoma
REPTOR™
Next-Gen Sequencing Bulk B Cells
REPTOR™
Next-Gen Sequencing Hit Expansion
REPTOR™
Next-Gen Sequencing Display Library
ALICANTO®
Rabbit Monoclonal Antibody Discovery
ALICANTO®
Single Domain (VHH) Antibody Discovery
ALICANTO®
Human Antibody Discovery
VALENS™
Protein Sequence Confirmation
VALENS™
Antibody Protein Sequencing
Get In Touch
Tell Us About Your Project.
Need more information? We’re here to answer any questions you have.
What Our Partners Are Saying About Us
I have had great experiences using Abterra Bio’s Reptor platform. The data generated was highly valuable, and the team provided quick and open communication throughout the whole process.
I would strongly recommend the services, Valens and Reptor, from Abterra Bio. Not only were the individuals extremely helpful throughout the development of my project, but they were always available to answer any questions I had throughout the project. Best of all, Abterra provided high-quality sequences with a rapid turnover which allowed my lab to continue our research with little delay.
Scientific Updates
New Service: Alicanto for Antibody Discovery from Human Serum
New Service: Alicanto for Antibody Discovery from Human SerumWe recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster...
Case Study: Reptor Phage Enrichment
Case Study: Phage EnrichmentProject Summary: Phage display is a powerful toolkit for antibody discovery and engineering. In this study, we used phage display to identify Cas9-binding single domain...
Advantages of High-Throughput Hybridoma Sequencing with NGS
Having a diverse collection of leads at the beginning of your antibody development campaign is critical for downstream success. As we know well, the immune response to immunization often focuses on...